The Federal Court of Appeal (FCA) dismissed an appeal by Biogen and a cross-appeal by Taro from a decision of the Federal Court... dismissing two actions by Biogen under the Patented Medicines (Notice of Compliance)...more
9/1/2022
/ Anticipation ,
Appeals ,
Canada ,
Dismissals ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patented Medicines ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
PMNOC Regulations
In a patent infringement action brought under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations, in relation to sitagliptin phosphate monohydrate (Merck’s JANUVIA), Justice Furlanetto of the Federal...more
4/28/2022
/ Canada ,
Intellectual Property Protection ,
Merck ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Validity ,
Patented Medicines ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
The Federal Court of Appeal (FCA) dismissed an appeal by Merck from a decision of the Federal Court... dismissing Merck’s application for judicial review of Health Canada’s refusal to add Canadian Patent No. 2,830,806 (806...more
12/3/2021
/ Appeals ,
Biologics ,
Deadlines ,
Dismissals ,
Health Canada ,
Judicial Review ,
Patent Registration ,
Patented Medicines ,
Patents ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Standard of Review